

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

MJ

RRID:CVCL_1414

Type: Cell Line

Proper Citation

ATCC Cat# CRL-8294, RRID:CVCL_1414

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1414

Proper Citation: ATCC Cat# CRL-8294, RRID:CVCL_1414

Description: Cell line MJ is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Primary cutaneous T-cell non-Hodgkin lymphoma

Defining Citation: [PMID:6604130](#), [PMID:7662981](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MJ

Synonyms: G11

Cross References: CLO:CLO_0007731, EFO:EFO_0002237, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ATCC:CRL-8294, BCRC:60543, BioSample:SAMN03471200, BioSample:SAMN10987950, cancercellines:CVCL_1414, Cell_Model_Passport:SIDM01692, Cosmic:908137, DepMap:ACH-000077, GEO:GSM887322, GEO:GSM888398, IARC_TP53:21504, IGRhCellID:MJ, LiGeA:CCLE_874, LINCX_LDP:LCL-1142, PharmacDB:MJ_933_2019, Progenetix:CVCL_1414, Wikidata:Q54905784

ID: CVCL_1414

Vendor: ATCC

Catalog Number: CRL-8294

Record Creation Time: 20220427T220809+0000

Record Last Update: 20260905T181148+0000

Ratings and Alerts

No rating or validation information has been found for MJ.

No alerts have been found for MJ.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mukherjee D, et al. (2025) IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1 α -Cofilin-1 Axis in Cutaneous T-cell Lymphoma. Molecular cancer research : MCR, 23(9), 807.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer research communications, 4(6), 1441.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell reports, 29(8), 2321.